J&J says Darza­lex, Carvyk­ti dri­ve Q1 phar­ma sales growth while medtech looms large

John­son & John­son re­leased its first quar­ter fi­nan­cial re­port Mon­day morn­ing, high­light­ing a sales growth of 2.3% to $21.4 bil­lion and tout­ing an 8.3% growth in world­wide in­no­v­a­tive med­i­cine sales dri­ven by Darza­lex and Carvyk­ti, among oth­ers.

Sales of its can­cer drug Darza­lex hit $2.69 bil­lion for the quar­ter and was ahead of most con­sen­sus, with $1.4 bil­lion com­ing from the US and $1.22 bil­lion in the rest of the world, ac­cord­ing to a press re­lease from li­cens­ing part­ner Gen­mab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER